Trial Profile
A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Celgene Corporation
- 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Jun 2013 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 06 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.